ArticleBMC infectious diseases2025
Adherence to on-demand and daily oral pre-exposure prophylaxis for HIV among men who have sex with men in China: a cross-sectional study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPre-exposure prophylaxis (PrEP) has been effective in reducing HIV transmission in men who have sex with men (MSM). The effectiveness of PrEP is closely related to adherence, whether taken daily or on-demand. In China, there are few studies on PrEP adherence in MSM.
methodsAn online survey was conducted on the Heer Health Platform from July 6 to August 30, 2022. Participants were recruited through private messages sent to users who had purchased PrEP on the platform. The primary outcome was the proportion of daily and on-demand PrEP usage. Secondary outcomes included the proportions of high and low adherence to daily and on-demand PrEP among MSM. Univariate analyses were performed using the chi-square test or fisher's exact test, followed by multivariate logistic regression to identify factors associated with PrEP adherence.
resultsAmong 384 participants, comprising 321 (83.6%) on-demand and 63 (16.4%) daily PrEP users. High adherence was observed in all daily users (100%) versus 81.9% (263) of on-demand users. During their last on-demand PrEP cycle, 8.7% (28/321) did not take the third pill on time, with 60.7% (17/28) delayed by over 2 h. 10.6% (34/321) missed the fourth pill, with 76.5% (26/34) delayed exceeded 2 h. Primary reasons were forgetting and busy schedules. Multivariable logistic regression identified three independent predictors of high adherence among on-demand PrEP users, including regular follow-up during PrEP use, having an HIV-positive sexual partner not on antiretroviral therapy and PrEP consultation (P < 0.05). Besides, statistically significant differences were found in variables such as sexuality, regular follow-up while taking PrEP, the number of male sexual partners in the last six months, the HIV status of the most recent male sexual partner in the past six months, and perceived HIV infection risk between the high adherence groups of on-demand and daily PrEP (P < 0.05).
conclusionsGovernment and health authorities should continue to increase awareness and promotion of PrEP and condoms use among MSM. Emphasizing the importance of non-missing dose resolutions and regular follow-up can help improve PrEP adherence among MSM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.